Literature DB >> 16801674

Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy.

Mathew Pulicken1, Ayman Koteish, Karen DeBusk, Peter A Calabresi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16801674     DOI: 10.1212/01.wnl.0000219764.27182.c7

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

Review 1.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

2.  Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.

Authors:  Helmut Neumann; Antal Csepregi; Michael Sailer; Peter Malfertheiner
Journal:  J Neurol       Date:  2007-03-12       Impact factor: 4.849

3.  Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.

Authors:  Naila Makhani; Bo-yee Ngan; Binita M Kamath; E Ann Yeh
Journal:  Neurology       Date:  2013-07-24       Impact factor: 9.910

4.  Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.

Authors:  Robert J Fontana; Paul Hayashi; Herbert L Bonkovsky; David E Kleiner; Sweta Kochhar; Jiezhun Gu; Marwan Ghabril
Journal:  Dig Dis Sci       Date:  2013-02-02       Impact factor: 3.487

Review 5.  Safety, Tolerability, and Immunogenicity of Interferons.

Authors:  Michael G Tovey; Christophe Lallemand
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-20

Review 6.  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

Authors:  Marco Biolato; Assunta Bianco; Matteo Lucchini; Antonio Gasbarrini; Massimiliano Mirabella; Antonio Grieco
Journal:  CNS Drugs       Date:  2021-07-28       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.